

‘Multimodal motor symptoms quantification platform for individualized Parkinson’s disease treatments’ MuSyQ

<https://neurodegenerationresearch.eu/survey/multimodal-motor-symptoms-quantification-platform-for-individualized-parkinsons-disease-treatments-musyq/>

Question

Principal Investigators

Anders Ericsson

Related

Institution

ACREO SWEDISH ICT AB

Contact information of lead PI

Country

Sweden

Title of project or programme

‘Multimodal motor symptoms quantification platform for individualized Parkinson’s disease treatments’ MuSyQ

Source of funding information

VINNOVA

Total sum awarded (Euro)

€ 391,730

Start date of award

19-11-2014

Total duration of award in years

2.0

The project/programme is most relevant to:

Parkinson's disease & PD-related disorders

Keywords

Research Abstract

In this project, university hospitals, universities, research institutes and small enterprises are collaborating to develop a platform for quantification of the motor symptoms associated with Parkinson's disease in a home setting. This platform offers the possibility of objective characterization of the health status of the patient at closer intervals than done today, and thus the ability to detect improvement and/or worsening of symptoms more easily. Within this project the evaluation of motor symptoms will be linked to pharmaceutical treatment, which will facilitate dosage titration and thus improve everyday life for the patient. This unique project constellation will not only develop a new sensor platform by combining three existing technologies, but will also work towards developing a new process for drug setting and dosage titration for Parkinson's disease patients. To improve user friendliness both for patients and healthcare personnel, treating physicians and other healthcare professionals as well as the Parkinson association are associated with this project. Our hope is that this project leads to the possibility for implementation in the healthcare system of an objective assessment of patient status in the home setting. This would result in increased efficiency of the treatment process, increased quality of life for the patient as well as an increased cost efficient for health care.

Lay Summary

Further information available at:

Types:

Investments > €500k

Member States:

Sweden

Diseases:

Parkinson's disease & PD-related disorders

Years:

2016

Database Categories:

N/A

Database Tags:

N/A